Connecticut is currently home to 1256 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
NCT06384352
Recruiting
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven, Connecticut
Conditions: Advanced Solid Tumors
Register for Updates
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT06315491
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Register for Updates
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
NCT05351801
Recruiting
Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differ... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/11/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Diabetic Neuropathic Pain, Peripheral Neuropathic Pain
Register for Updates
Gastroschisis Outcomes of Delivery (GOOD) Study
NCT02774746
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Gastroschisis
Register for Updates
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
NCT06812390
Recruiting
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: West Haven VA Medical Center, West Haven, Connecticut
Conditions: Cirrhosis, Ascites Hepatic
Register for Updates
SNV1521 in Participants with Advanced Solid Tumors
NCT06220864
Recruiting
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Register for Updates
SV2 PET Imaging with [11C]APP311
NCT03995121
Recruiting
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/10/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
Register for Updates
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Venous Thromboembolism
Register for Updates
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT06275126
Recruiting
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participa... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
03/07/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Register for Updates
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Yale University / Connecticut Mental Health Center, New Haven, Connecticut
Conditions: Obsessive-Compulsive Disorder
Register for Updates
Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study
NCT06111768
Recruiting
The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/06/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Cardiorenal Syndrome
Register for Updates
AMPK-activation by Metformin in FSGS: AMP-FSGS
NCT06090227
Recruiting
The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/06/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates